Sauveur-Michel Maira
Novartis (Switzerland)(CH)Novartis Institutes for BioMedical Research
Publications by Year
Research Areas
PI3K/AKT/mTOR signaling in cancer, Chronic Lymphocytic Leukemia Research, Melanoma and MAPK Pathways, Lung Cancer Treatments and Mutations, Synthesis and biological activity
Most-Cited Works
- → Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity(2008)1,147 cited
- → The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations(2008)563 cited
- → Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor(2011)525 cited
- → Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials(2014)491 cited
- → ERα-Dependent E2F Transcription Can Mediate Resistance to Estrogen Deprivation in Human Breast Cancer(2011)333 cited
- → Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells(2009)318 cited
- → Carboxyl-Terminal Modulator Protein (CTMP), a Negative Regulator of PKB/Akt and v-Akt at the Plasma Membrane(2001)261 cited
- → mTOR Inhibitor RAD001 (Everolimus) Has Antiangiogenic/Vascular Properties Distinct from a VEGFR Tyrosine Kinase Inhibitor(2009)251 cited
- → NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas(2009)250 cited
- → Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer(2011)249 cited